메뉴 건너뛰기




Volumn 57, Issue 1, 2013, Pages 23-30

Impact of added fluvastatin to standard-of-care treatment on sustained virological response in Naïve chronic hepatitis C patients infected with genotypes 1 and 3

Author keywords

Chronic hepatitis C; Fluvastatin; Pegylated interferon ; Ribavirin; Sustained virological response

Indexed keywords

CREATINE KINASE; FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

EID: 84889817131     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000354541     Document Type: Article
Times cited : (14)

References (37)
  • 1
    • 23944506014 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis C virus infection
    • Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
    • (2005) Lancet Infect Dis , vol.5 , pp. 558-567
    • Shepard, C.W.1    Finelli, L.2    Alter, M.J.3
  • 2
    • 36549067746 scopus 로고    scopus 로고
    • The changing epidemiology of hepatitis C virus infection in Europe
    • Esteban JI, Sauleda S, Quer J: The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162.
    • (2008) J Hepatol , vol.48 , pp. 148-162
    • Esteban, J.I.1    Sauleda, S.2    Quer, J.3
  • 3
    • 45249120854 scopus 로고    scopus 로고
    • Lichen planus and other cutaneous manifestation in chronic hepatitis C: Pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area
    • Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L: Lichen planus and other cutaneous manifestation in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereal 2008; 22: 779-788.
    • (2008) J Eur Acad Dermatol Venereal , vol.22 , pp. 779-788
    • Maticic, M.1    Poljak, M.2    Lunder, T.3    Rener-Sitar, K.4    Stojanovic, L.5
  • 5
    • 79960453276 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of hepatitis C virus infection
    • European Association for the Study of the Liver
    • European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
    • (2011) J Hepatol , vol.55 , pp. 245-264
  • 7
    • 74049109303 scopus 로고    scopus 로고
    • Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients
    • Giannini EG, Basso M, Savarino V, Piccotto A: Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502-508.
    • (2010) Aliment Pharmacol Ther , vol.31 , pp. 502-508
    • Giannini, E.G.1    Basso, M.2    Savarino, V.3    Piccotto, A.4
  • 12
    • 28844451934 scopus 로고    scopus 로고
    • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    • Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J: Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
    • (2006) J Hepatol , vol.44 , pp. 97-103
    • Zeuzem, S.1    Buti, M.2    Ferenci, P.3    Sperl, J.4    Horsmans, Y.5    Cianciara, J.6    Ibranyi, E.7    Weiland, O.8    Noviello, S.9    Brass, C.10    Albrecht, J.11
  • 15
    • 33747797031 scopus 로고    scopus 로고
    • Treating viral hepatitis C: Efficacy, side effects, and complications
    • Manns MP, Wedemeyer H, Cornberg M: Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359.
    • (2006) Gut , vol.55 , pp. 1350-1359
    • Manns, M.P.1    Wedemeyer, H.2    Cornberg, M.3
  • 16
    • 0043037223 scopus 로고    scopus 로고
    • High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C
    • Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
    • (2003) Hepatology , vol.38 , pp. 639-644
    • Bressler, B.L.1    Guindi, M.2    Tomlinson, G.3    Heathcote, J.4
  • 17
    • 65449136656 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C: An update
    • Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3    Seeff, L.B.4
  • 18
    • 14044265120 scopus 로고    scopus 로고
    • Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids
    • Kapadia SB, Chisari FV: Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102: 2561-2566.
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 2561-2566
    • Kapadia, S.B.1    Chisari, F.V.2
  • 19
    • 0346103657 scopus 로고    scopus 로고
    • Disruption of hepatits C virus RNA replication through inhibition of host protein geranylgeranylation
    • Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr: Disruption of hepatits C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003; 100: 15865-15870.
    • (2003) Proc Natl Acad Sci USA , vol.100 , pp. 15865-15870
    • Ye, J.1    Wang, C.2    Sumpter Jr., R.3    Brown, M.S.4    Goldstein, J.L.5    Gale Jr., M.6
  • 20
    • 33745903898 scopus 로고    scopus 로고
    • Different anti-HCV profiles of statins and their potential for combination therapy with interferon
    • Ikeda M, Abe K, Yamada M, Danasko H, Naka K, Kato N: Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-125.
    • (2006) Hepatology , vol.44 , pp. 117-125
    • Ikeda, M.1    Abe, K.2    Yamada, M.3    Danasko, H.4    Naka, K.5    Kato, N.6
  • 21
    • 79951867601 scopus 로고    scopus 로고
    • National guidelines for the management of hepatitis C virus infection in drug users in Slovenia
    • Maticic M, Kastelic A: National guidelines for the management of hepatitis C virus infection in drug users in Slovenia. Zdrav Vestn 2009; 78: 529-539.
    • (2009) Zdrav Vestn , vol.78 , pp. 529-539
    • Maticic, M.1    Kastelic, A.2
  • 22
    • 0029778988 scopus 로고    scopus 로고
    • An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group
    • Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
    • (1996) Hepatology , vol.24 , pp. 289-293
    • Bedossa, P.1    Poynard, T.2
  • 25
    • 64549132866 scopus 로고    scopus 로고
    • An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads
    • Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miyakawa Y, Kumada H: An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009; 52: 43-48.
    • (2009) Intervirology , vol.52 , pp. 43-48
    • Sezaki, H.1    Suzuki, F.2    Akuta, N.3    Yatsuji, H.4    Hosaka, T.5    Kobayashi, M.6    Suzuki, Y.7    Arase, Y.8    Ikeda, K.9    Miyakawa, Y.10    Kumada, H.11
  • 26
    • 80054883954 scopus 로고    scopus 로고
    • Potential enhancement of both early (EVR) and sustained (SVR) virological response by fluvastatin in chronic hepatitis C treated with standard PEGIFN-RIBAVIRIN therapy. A pilot study
    • Georgescu EF, Streba L, Teodorescu R, Mateescu G, Tataru Abagiu M: Potential enhancement of both early (EVR) and sustained (SVR) virological response by fluvastatin in chronic hepatitis C treated with standard PEGIFN-RIBAVIRIN therapy. A pilot study. J Hepatol 2011; 54:S5-S6.
    • (2011) J Hepatol , vol.54
    • Georgescu, E.F.1    Streba, L.2    Teodorescu, R.3    Mateescu, G.4    Tataru Abagiu, M.5
  • 28
    • 77952557164 scopus 로고    scopus 로고
    • Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C genotype 1 co-infected patients: An open-label randomized controlled study
    • Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, Galli M, Antinori S: Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother 2010; 65: 735-740.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 735-740
    • Milazzo, L.1    Caramma, I.2    Mazzali, C.3    Cesari, M.4    Olivetti, M.5    Galli, M.6    Antinori, S.7
  • 32
    • 33645889332 scopus 로고    scopus 로고
    • Final conclusions and recommendations of the national lipid association statin safety assessment task force
    • McKenney JM, Davidson MH, Jacobson TA, Guyton JR: Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97: 89C-94C.
    • (2006) Am J Cardiol , vol.97
    • McKenney, J.M.1    Davidson, M.H.2    Jacobson, T.A.3    Guyton, J.R.4
  • 34
    • 80052783050 scopus 로고    scopus 로고
    • Building and applying logistic regression models
    • in Agresti A (ed): Hoboken, John Wiley
    • Agresti A: Building and applying logistic regression models; in Agresti A (ed): An Introduction to Categorical Data Analysis. Hoboken, John Wiley, 2007, p 138.
    • (2007) An Introduction to Categorical Data Analysis , pp. 138
    • Agresti, A.1
  • 35
    • 67651150050 scopus 로고    scopus 로고
    • Statins potentiate the in vitro antihepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development
    • Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J: Statins potentiate the in vitro antihepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50: 6-16.
    • (2009) Hepatology , vol.50 , pp. 6-16
    • Delang, L.1    Paeshuyse, J.2    Vliegen, I.3    Leyssen, P.4    Obeid, S.5    Durantel, D.6    Zoulim, F.7    Op De-Beeck, A.8    Neyts, J.9
  • 37
    • 0032937343 scopus 로고    scopus 로고
    • The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
    • Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27: 410-416.
    • (1999) Drug Metab Dispos , vol.27 , pp. 410-416
    • Fischer, V.1    Johanson, L.2    Heitz, F.3    Tullman, R.4    Graham, E.5    Baldeck, J.P.6    Robinson, W.T.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.